Some studies suggest that c-Met is a stronger prognostic indicator of poor prognosis than traditional markers such as Her2/neu and epidermal growth factor receptor (EGFR) [17–19], whereas others show no statistically significant relation between c-Met and prognosis in breast cancer [20, 21]. Here, EGFR is linked to breast carcinoma.